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Abstract
Background: Head and Neck squamous cell carcinoma (HNSCC) is a human lethal cancer with clinical, pathological,
phenotypical and biological heterogeneity. Caner initiating cells (CICs), which are responsible for tumor growth and coupled
with gain of epithelial-mesenchymal transition (EMT), have been identified. Previously, we enriched a subpopulation of head
and neck cancer initiating cells (HN-CICs) with up-regulation of CD133 and enhancement of EMT. Others demonstrate that
Src kinase interacts with and phosphorylates the cytoplasmic domain of CD133. However, the physiological function of
CD133/Src signaling in HNSCCs has not been uncovered.
Methodology/Principal Finding: Herein, we determined the critical role of CD133/Src axis modulating stemness, EMT and
tumorigenicity of HNSCC and HN-CICs. Initially, down-regulation of CD133 significantly reduced the self-renewal ability and
expression of stemness genes, and promoted the differentiation and apoptotic capability of HN-CICs. Additionally,
knockdown of CD133 in HN-CICs also lessened both in vitro malignant properties including cell migration/cell invasiveness/
anchorage independent growth, and in vivo tumor growth by nude mice xenotransplantation assay. In opposite,
overexpression of CD133 enhanced the stemness properties and tumorigenic ability of HNSCCs. Lastly, up-regulation of
CD133 increased phosphorylation of Src coupled with EMT transformation in HNSCCs, on the contrary, silence of CD133 or
treatment of Src inhibitor inversely abrogated above phenotypic effects, which were induced by CD133 up-regulation in
HNSCCs or HN-CICs.
Conclusion/Significance: Our results suggested that CD133/Src signaling is a regulatory switch to gain of EMT and of
stemness properties in HNSCC. Finally, CD133/Src axis might be a potential therapeutic target for HNSCC by eliminating HN-
CICs.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is one of
the most common cancers in the world and one of causes of
cancer-related death due to therapy resistance [1]. Despite of im-
provements in the diagnosis and treatment of HNSCC, the overall
long-term survival rates have improved marginally over the past
decade [2].
Accumulating data demonstrate that tumor formation is driven
by a subpopulation of cells that exhibit self-renewal capacity–the
purported cancer stem cells (CSCs) or cancer initiating cells (CICs)
[3,4]. CICs have been shown to have the capacity to promote
tumor progression and metastasis, and also contribute to radio-
resistance and chemo-resistance [5]. Recently, we and others have
verified the existence of CICs in HNSCC (HN-CICs) [6,7,8,9].
However, there is lack of evidence how cell surface signaling
modulating the intracellular stemness properties or tumorigenicity
of HN-CICs.
CD133 (prominin-1), a 5-transmembrane glycoprotein, was
originally recognized as a hematopoietic stem cells marker [10].
Consequently, CD133 has been considered as an important cell
surface marker to represent the subpopulation of CICs in brain
tumors, colon carcinoma, prostate carcinoma, hepatocellular
carcinoma, thyroid carcinoma and head and neck cancer
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that the up regulation of CD133 in HN-CICs, further, the up-
regulation of C133 in HNSCC cancerous tissue is negatively
correlated with the survival prognosis of HNSCC patients [8].
Recent reports also suggest that expression of CD133 in tumor
tissues could serve as a prognostic indicator for tumor re-growth,
malignant progression, and patient survival [19,20,21]. Neverthe-
less, the CD133 mediated molecular mechanisms in regulating
CICs in HNSCC is still unclear.
EMT, a cellular transformation that converts adherent
epithelial cells into migratory mesenchymal cells, is critical for
embryonic development and tumorigenic progression of cancer
cells and cancer metastasis [22]. Researchers have shown that
EMT could promote stem cells (SCs) properties and further
generate cells with the features of tumor initiating property
[23,24]. EMT program also significantly maintained tumor
initiating cells property in HNSCC [6,7,25].
Src, a classical non-receptor tyrosine kinase with the potential to
cause cell transformation including uncontrolled proliferation and
loss of contact inhibition, becomes activated by interacting with
the stimulated membrane receptors [26]. The extracellular signal
would be further amplified and transduced through interaction
between activated Src and downstream targets such as Ras/
MAPK, PI3K/AKT and STAT3 pathways [26]. Activation of Src
disrupts cell-cell junction, promotes invasiveness through the
phosphorylation of b-catenin thus causing the degradation of E-
cadherin, and subsequently triggers the EMT [27]. Further, Boivin
et al demonstrate that CD133 is a novel binding partner of Src
and is phosporylated by Src kinase [28].
The detailed molecular mechanisms involved in the regulatory
links between EMT and stem cell–related genes such as CD133 and
Src are still poorly understood. Herein, we demonstrate a critical
role of CD133 in the enhancement of stemness, gain of EMT,
and promoting tumorigenicity of HN-CICs. Additionally, down-
regulation of CD133 or inhibition of CD133 induced Src activation
lessens stemness properties and tumorigenicity of HNSCCs both
in vitro and in vivo. Ultimately, we demonstrate the significance of
CD133/Src signaling on EMT process in HNSCC.
Materials and Methods
Cell lines cultivation and enrichment of HN-CICs from
HNSCCs
Two HNSCC cell lines, SAS [29] and OECM1[30], were
grown in DMEM or in RPMI supplemented with 10% FBS
(Grand Island, NY), respectively. One primary HNSCC cell line
was obtained from HNSCC patient. All of the clinical samples in
this study were approved and in accordance with the Institutional
Review Board of Chung Shan Medical University Hospital
(CSMUH No: CSI0249). For enrichment of HN-CICs, the two
cell lines were cultured in tumor sphere medium consisting of
serum-free DMEM/F12 medium (GIBCO), N2 supplement
(GIBCO), 10 ng/mL human recombinant basic fibroblast growth
factor-basic (FGF) and 10 ng/mL Epidermal Growth Factor
(EGF) (R&D Systems, Minneapolis, MN). Cells were plated at a
density of 7.5610
4 to 1610
5 live cells/10-mm dishes, and the
medium was changed every other day until the tumor sphere
formation was observed in about 4 weeks [8].
Stable overexpression of CD133 in HNSCC cells
Human CD133 gene was amplified from human fetal lung and
spleen cDNA template obtained from Biosettia Inc. (Cat. No.
cDNA-hsa-09; San Diego, CA, USA) and then cloned into
pCDH1-MCS1-EF1-copGFP (System Biosciences, Cat. No:
CD511A-1; Mountain View, CA, USA). The sequences of oligos
used for CD133 PCR amplification are 59-ACCGTCTAGAATG-
GCCCTCGTACTCGGCTCCCTGTTGCTG-39 and 59- ATCA-
AAGCTTATTGAAGCTGTTCTGCAGGTGAAGAG- tgcc-39.
Lentivirus production was performed by co-transfection of plasmid
DNA mixture with lentivector plus helper plasmids (VSVG and
Gag-Pol) into 293T cells (American Type Culture Collection,
Manassas, VA) using Lipofectamine 2000 (LF2000, Invitrogen,
Calsbad, CA, USA). The lentivirus M.O.I titer is determined by
flow cytometry (average of 5610
4 and 2610
5 TU/ml). To generate
the stable cell lines, sub-confluent HNSCC cells were infected with
lentivirus in the presence of 8 mg/ml polybrene (Sigma-Aldrich, St
Louis, MO, USA). The green fluorescence protein (GFP), which
was co-expressed in lentiviral-infectedcells, was servedas a selection
marker to indicate the successfully infected HNSCCs. Stable
CD133-overexpressing HNSCC cell lines were further purified by
cell sorting with GFP positive cells (Figures 1A and 1B). The
pCDH1-MCS1-EF1-copGFP empty vector alone is utilized for
experimental control.
Construction of Lentiviral-mediated RNAi for silencing
CD133
The pLV-RNAi vector, which co-expressing GFP protein in
infected host cells, was purchased from Biosettia Inc. (Biosettia,
San Diego, CA, USA). The method of cloning the double-
stranded shRNA sequence is described in the manufacturer’s
protocol. Lentiviral vectors expressing shRNA that targets human
CD133 (oligonucleotide sequence: Sh-CD133-1:59-AAAAGGAC-
AAGGCGTTCACAGATTTGGATCCAAATCTGTGAACGCC-
TTGTCC-39; Sh-CD133-2:59-AAAAGGATACACCCTACTTAC-
TATTGGATCCAATA GTAAGTAGGGTGTATCC-39)w e r es y n -
thesized and cloned into pLVRNAi to generate a lentiviral expression
vector. Sh-Luc:59-CCGGACTTACGCTGAGTACTTCGAA CT-
CGAGTTCGAAGTACTCAGCGTAAGTTTTTTG-39 was uti-
lized for experimental control. Lentivirus production was performed
as above. Stable pLV-RNAi expressed HNSCC cell lines were further
purified by cell sorting with GFP positive cells (Figure S1C).
Side population analysis
For side population analysis, single HNSCC cells suspension at
1610
6/ml was prepared in pre-warmed DMEM medium with 2%
fetal bovine serum (FBS). Hoechst 33342 dye was then added at a
final concentration of 5 mg/ml in the presence or absence of
fumitremorgin C (FTC) (10 mM; Sigma, St Louis, MO, USA) and
was incubated at 37uC for 90 min with intermittent shaking. The
cells were washed with ice-cold HBSS with 2% FBS and
centrifuged at 4uC, and re-suspended in the same buffer.
Propidium iodide at a final concentration of 2 mg/ml was added
for gating viable cells. The Hoechst 33342 dye was excited at
357 nm and its fluorescence was dual-wavelength analyzed (blue,
402–446 nm; red, 650–670 nm). Analyses were done on a FACS
Vantage (BD, San Diego, CA, USA) [6].
Apoptotic Assay
Apoptotic cells were detected with an Annexin V-APC kit
(Calbiochem, Darmstadt, Germany) according to manufacturer’s
guidelines. After staining, the cells incubated with 20 mg/ml
propidum iodide (PI) were analyzed by FACS Calibur apparatus
(Becton Dickinson, San Diego, CA, USA) [6].
In vitro cell migration and invasion assay
For transwell migration assays, 2610
5 cells were plated into the
top chamber of a transwell (Corning, Acton, MA) with a porous
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PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e28053Figure 1. Depletion of CD133 impairs self-renewal property but inversely increases differentiation and apoptotic activity of HN-
CICs. (A) Single cell suspension of HN-CICs was transduced with sh-Luc or sh-CD133 lentivirus for 3 days. Total proteins prepared from infected cells
were prepared and analyzed. The silencing effect of CD133 shRNA in HN-CICs was validated translationally by western blotting (OECM1 (left panel)
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lower serum (0.5% FBS), and medium supplemented with higher
serum (10% FBS) was used as a chemoattractant in the lower
chamber. The cells were incubated for 24 h at 37uC and cells that
did not migrate through the pores were removed by a cotton swab.
Cells on the lower surface of the membrane were stained with
Hoechst 33258 (Sigma-Aldrich) to show the nuclei; fluorescence
was detected at a magnification of 100x using a fluorescence
microscope (Carl Zeiss, Oberkochen, Germany). The number of
fluorescent cells in a total of five randomly selected fields was
counted. In vitro cell invasion analysis was described previously
[8].
Soft agar colony forming assay
Each well (35 mm) of a six-well culture dish was coated with
2 ml bottom agar (Sigma-Aldrich) mixture (DMEM, 10% (v/v)
FCS, 0.6% (w/v) agar). After the bottom layer was solidified, 2 ml
top agar-medium mixture (DMEM, 10% (v/v) FCS, 0.3% (w/v)
agar) containing 2610
4 cells was added, and the dishes were
incubated at 37uC for 4 weeks. Plates were stained with 0.005%
Crystal Violet then the colonies were counted. The number of
total colonies with a diameter $100 mm was counted over five
fields per well for a total of 15 fields in triplicate experiments.
Subcutaneous xenografts in nude mice
All the animal practices in this study were approved and in
accordance with the Institutional Animal Care and Use Commit-
tee (IACUC) of National Yang-Ming University, Taipei, Taiwan
(IACUC approval No. 961230). Stable sh-Luc and sh-CD133
HN-CICs or control GFP and CD133-overexpresiing HNSCCs
mixed with Matrigel (BD bioscience, San Diego, CA, USA) (1:1)
were injected subcutaneously into BALB/c nude mice (6–8 weeks).
Tumor volume (TV) was calculated using the following formula:
TV (mm
3) = (Length 6Width
2)/2.
Statistical analysis
Statistical Package of Social Sciences software (version 13.0)
(SPSS, Inc., Chicago, IL) was used for statistical analysis. Student’s
t test was used to determine statistical significance of the
differences between experimental groups; p values less than 0.05
were considered statistically significant. The level of statistical
significance was set at 0.05 for all tests.
Results
Down-regulation of CD133 reduces stemness properties
coupled with increased differentiation and apoptotic
capabilities in HN-CICs
We have identified a subpopulation of head and neck cancer
initiating cells (HN-CICs) with enhanced stemness properties from
HNSCC cells (HNSCCs) by sphere formation assay [8].
Additionally, we and others display up-regulation of CD133 in
HN-CICs [8,31,32]. To further investigate whether CD133 plays
a role in maintaining CICs properties of HN-CICs, the approach
of loss-of-function of CD133 was first conducted. Down-regulation
of CD133 in HN-CICs was achieved by viral transduction with
lentiviral vector expressing small hairpin RNA (shRNA) targeting
CD133 (sh-CD133-1 and sh-CD133-2), and lentiviral vector
expressing shRNA against luciferase (sh-Luc) was used as control.
Immunoblotting analyses confirmed that lentivirus expressing both
sh-CD133-1 and sh-CD133-2 markedly reduced the expression
level of CD133 protein in transduced HN-CICs (Figure 1A). Cell
population with surface CD133-positive (CD133
+) was also
decreased in sh-CD133 infected HN-CICs by FACS analyses
(Figure 1B). Furthermore, HN-CICs infected with sh-CD133
lentivirus did not maintain floating spheres but showed more
attached epithelial-like cells (Figure 1C). We also observed reduced
expression of stemness genes (Oct-4 and Nanog) (Figure 1A) but
the enhanced expression of epithelial differentiation marker,
CK18 (Figure 1D) in CD133 knockdown HN-CICs. To further
determine whether the reduction in tumor sphere formation
efficiency with CD133 down-regulation was due to decreased HN-
CICs survival, we examined the apoptotic cells using Annexin V
plus propidium iodide (PI) staining. HN-CICs infected with sh-
CD133 expressing lentivirus significantly increased the percentage
of Annexin V
+/PI
+ cells (Figure 1E). Together, these data further
support that down-regulation of CD133 resulted in a reduction of
CICs properties and cell viability in HN-CICs.
Targeting CD133 abrogates in vitro and in vivo malignant
properties of HN-CICs
To elucidate the direct effect of CD133 knockdown on in vitro
malignant properties including abilities of cell migration, matrigel
invasion and anchorage independent growth of HN-CICs, single
cell suspension of control- or CD133- knockdown HN-CICs were
plated onto Transwell chamber (Figure 2A), Transwell chamber
coated with matrigel (Figure 2B) or into soft agar (Figure 2C), and
analyzed. The migratory/invasion/colony formation abilities of
CD133 knockdown HN-CICs were significantly reduced
(Figures 2A, 2B and 2C). We next sought to determine if down-
regulation of CD133 expression could attenuate the tumorigenic
ability of HN-CICs in vivo. Of note, inhibition of CD133
expression significantly slowed down the tumor growth mediated
by HN-CICs (Figures 2D and 2E; p,0.05; p,0.01). In addition,
the immunohistological staining of tumors derived from sh-CD133
HN-CICs displayed decrease of Oct4 and increase of CK18 in
comparison to those from control HN-CICs tumors (Figure S2A
and S2B). Overall, our data indicate that depletion of CD133
inhibits tumor initiating activity of HN-CICs in vivo.
Overexpression of CD133 enhances stemness properties
and tumorigenic potentials of HNSCCs
To further investigate the effect of CD133 up-regulation
on biological properties of HNSCCs, we generated stable
CD133-overexpressing HNSCCs through lentiviral-mediated
transduction. The successful infection rate of control-GFP and
CD133-overexpressing HNSCCs, afterward the cell sorting,
ranged from 93 to 94% (OECM1) and 97 to 91% (SAS),
and SAS (right panel)). Immunoblotting against anti-Oct-4, anti-Nanog, or anti-GAPDH antibodies was performed as indicated. The amount of GAPDH
protein of different crude cell extracts was referred as loading control, and for further quantification. (B) Cell surface CD133 of sh-CD133-1, sh-CD133-
2 and sh-Luc HN-CICs was analyzed by flow cytometry (C) HN-CICs were first infected with sh-CD133-1, sh-CD133-2 or sh-Luc lentivirus for 3 days, and
then further cultivated under the serum-free defined selection medium. The cellular morphology of HN-CICs treated with sh-Luc or CD133-shRNA
lentivirus was examined. Arrows indicated the sphere cells. The expression profile of CK18 (D) or Annexin V vs. PI positive staining (E) of HN-CICs cells
infected with sh-CD133-1, sh-CD133-2 or sh-Luc lentivirus was assessed, respectively, by flow cytometry. The percentage of Annexin V
+/PI
+ double
positive cells was recorded (E; right panel). The control IgG was used to define the baseline signal in (B) and (D). The experiments were repeated three
times and the representative results were shown. Results are means 6 SD (*, p,0.05; ***, p,0.001).
doi:10.1371/journal.pone.0028053.g001
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e28053Figure 2. CD133 knockdown reduces migration/invasiveness/clonogenicity and impairs in vivo tumorigenic properties of HN-CICs.
To elucidate the capability of cell migration (A), cell invasiveness (B) and anchorage independent growth (C) of HN-CICs (OECM1 (upper panel), SAS
(lower panel)) with CD133 down-regulation, single cell suspension of HN-CICs infected with CD133-specific shRNA or control sh-Luc lentivirus for
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ing HNSCCs (OECM1 and SAS) displayed elevated expression of
CD133 by western blot analyses (Figure 3A). Further, we found
that compared to GFP expressing control cells the CD133-
overexpressing HNSCCs showed significant increasing of CD133
+
cells by FACS analyses (Figure 3B). In addition, the CD133-
overexpressing HNSCCs showed enhanced tumor sphere-forming
capacity (Figure 3C) and significant increasing of side population
(SP) cells (Figure 3D). We also observed that increased protein
level of Oct-4 and Nanog of CD133-overexpressing HNSCCs
under cultivation with defined serum-free medium (Figure 3E).
Next, we demonstrated that overexpression of CD133 also resulted
in increased ability on cell invasiveness and colony formation of
HNSCCs (Figures 4A and 4B). Of note, CD133-overexpressing
HNSCCs also showed significantly elevated tumorigenicity in
comparison to control HNSCCs by xenotransplantation analyses
in vivo (Figures 4C; p,0.05; p,0.01). In addition, IHC analyses
demonstrated that tumors derived from CD133-overexpressing
SAS cells displayed more Oct4 but less CK18 staining (Figure
S2C). Collectively, these results suggest that overexpression of
CD133 promotes stemness properties and tumorigenicity of
HNSCCs.
Src kinase is the downstream modulator of CD133 on
regulating EMT in HNSCC and HN-CICs
HNSCC epithelial cells can acquire mesenchymal traits which
facilitate migration and invasion through EMT process [7,33]. In
figures 4A, we showed that CD133 promotes invasive ability of
HNSCCs, we then wanted to explore whether CD133 would
modulate the EMT pathway. Morphological observation indicated
that overexpression of CD133 in epithelial-type OECM1 cells
revealed mesenchymal-like shape change (Figure 5A). Immuno-
fluorescence and immunoblotting staining displayed that an
epithelial-like protein expression pattern (E-Cadherin) was de-
creased but a mesenchymal-like protein expression pattern
(Vimentin and Fibronectin) was enhanced in CD133-overexpress-
ing HNSCCs (Figure 5B). On the other hand, silencing of CD133
reduced mesenchymal marker (Vimentin) but induced epithelial
markers (E-Cadherin) in HN-CICs (Figure 5C).
Src signaling pathway is an important mediator of the EMT in
HNSCC (Figure S3A) [34]. Fujimoto et al have showed that
tyrosin-513 within CD19 is not only Lyn (a Src family kinase)
binding site but also phosphorylation side, further, the interaction
between CD19 and Lyn would amplify the Src family kinase
activity and downstream cascade [35]. Boivin et al have
demonstrated that CD133 is a novel binding partner of Src and
is phosporylated by Src kinase [28]. However, how does the
interaction between CD133 and Src kinase activate the down-
stream effects including amplification of Src activity remain
unclear? Here, we demonstrated that p-Src (activated Src with
phosphorylation) was increased in CD133-overexpressing
HNSCCs (Figure 5D). On the contrary, CD133 silencing reduced
active Src in HN-CICs (Figure 5E). Consistently, treatment of Src
inhibitor (PP2) but not Erk1/2 inhibitor (U0126) significantly
reversed the mesenchymal-like protein expression pattern into an
epithelial-like one, and increased the expression of cytokeratin 18
(CK18), a differentiation marker, in CD133-overexpressing
OECM1 cells (Figure 5F). Overexpression of CD133 promotes
the phosphorylation of Erk1/2 in human glioblastoma cells [36],
but in our CD133-overexpressing HNSCCs, treatment of Erk1/2
inhibitor (U0126) caused only slight influence on CD133-
overexpressing induced EMT (Figure 5F and data not shown).
Lastly, PP2 treatment reduced stemness markers (Oct4 and
Nanog) and also impaired sphere formation ability of CD133-
overexpressing HNSCCs under cultivation with defined serum-
free medium (Figure 5G and data not shown).
CD133 downregulation and Src inhibition abrogate the
p-Src activity and sphere formation ability in primary
HN-CICs
To further verify the physiological function of CD133/Src axis
mediated signaling in primary HN-CICs, the HN-CICs derived
from primary HNSCC patient cells were generated. Further, the
expression of CD133 in HN-CICs was downregulated by
lentiviral-sh-RNAi. Consistently, the p-Src activity was also
downregulated (Figure 6A). In addition, the sphere formation
ability of sh-CD133 primary HN-CICs was decreased compared
to that of control (sh-Luc) primary HN-CICs (Figure 6B). Finally,
PP2 (inhibitor of Src activity) treatment to primary HN-CICs also
abolished the sphere formation capability (Figure 6C).
In Summary, our results suggested that CD133/Src signaling
plays a major switch on regulating CICs properties, EMT
transformation and tumorigenicity of HNSCCs (Figure 7).
Discussion
Tumor is composed of a heterogeneous population of cells, and
it has been observed that a subpopulation of cells, so called cancer
stem cells (CSCs) or cancer initiating cells (CICs), within tumor
tissues posses stemness properties [37]. CSCs or CICs are
considered to be responsible for the initiation, propagation and
metastasis of tumors [38,39,40]. Importantly, the existence of
CICs might explain cancer recurrences because of radioresistance
or chemoresistance after clinical treatment on cancer patients [5].
CD133, a cell surface marker of hematopoietic stem cells and
endothelial progenitors, has been proposed to be involved in the
angiogenesis as well as cancer tumorigenicity [41]. CD133 has
recently been identified as a common CICs marker for many
tumor types, including HNSCC [8,31]. Bao et al. find that the
subpopulation of CD133
+ cells isolated from brain tumors exhibit
CICs properties, are refractory to chemo- or radiotherapy, and
promote angiogenesis to facilitate the brain tumor growth [42].
Meanwhile, CD133
+ CICs in solid tumors characterized confer
resistance to chemotherapy [43]. On the contrary, CD133
depletion represses colony-forming ability of colon cancer [44].
Therefore, better understanding of the biological characteristics of
CD133
+ CICs may explain the failure of cancer management, and
will provide us with new therapeutic approaches [45].
Herein, we evaluated the role of CD133 in the maintenance of
stemness characteristics and tumorigenic potential of HNSCCs
and HN-CICs by lentiviral-mediated knockdown or overexpres-
sion of CD133 (Figures 1 and 3). Depletion of CD133 promoted
three days were plated onto transwell, transwell coated with matrigel and soft agar, respectively, and analyzed as described in Materials and
Methods. Results are means 6 SD of triplicate samples from three experiments. (D) Representative tumors of control HN-CICs and of CD133-
knockdown SAS-derived HN-CICs were generated, and the tumors were then dissected from the subcutaneous space of recipient mice (n=3)(Phase
contrast: left two panels; GFP imaging: right two panels) (Red arrows: sh-Luc HN-CICs; Yellow arrows: sh-CD133-1 HN-CICs). (E) Tumor volume was
measured, respectively, after inoculation of CD133-knockdown or sh-Luc–expressing SAS-derived HN-CICs. Error bars correspond to SD. (*, p,0.05;
***, p,0.001)
doi:10.1371/journal.pone.0028053.g002
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e28053Figure 3. Overexpression of CD133 in HNSSCs promotes stemness properties. (A) Expression of CD133 protein in HNSCCs infected with
either CD133-overexpressing or control GFP lentiviruse was examined by western blot. The amount of GAPDH protein was referred as loading
control. (B) Cell surface CD133 expression in CD133-overexpressing or control HNSCCs was analyzed by flow cytometry. (C) Representative images of
tumor sphere formation ability of control-GFP or CD133-overexpressing HNSCCs. (D) Single cell suspensions of stable CD133-overexpressing and
control GFP-expressing HNSCCs were incubated with Hoechst 33342 in the presence or absence of 10 mM fumitremorgin C (FTC), then, analyzed by
flow cytometry to identify the SP cells. (E) Total crude cell extracted proteins from control-GFP or CD133-overexpressing HNSCCs under cultivation
with defined serum-free medium for 2 weeks were prepared and immunoblotted against anti-Oct-4, anti-Nanog, anti-CK18 or anti-GAPDH antibodies
as indicated. The amount of GAPDH protein of different crude cell extracts was referred as loading control for further quantification.
doi:10.1371/journal.pone.0028053.g003
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e28053Figure 4. Overexpression of CD133 in HNSCCs enhances malignant activities. (A) The invasiveness ability of control-GFP or CD133-
overexpressing HNSCCs were examined as described in materials and methods (*, p,0.05; ***, p,0.001). (B) Anchorage-independent growth of
control-GFP or CD133-overexpressing HNSCCs was analyzed (**, p,0.01; ***, p,0.001). (C) Representative tumor growth of control-GFP or CD133-
overexpressing HNSCCs (1X10
5 cells) in the subcutaneous space of recipient mice (Red arrows: control-GFP HNSCCs; Yellow arrows: CD133-
overexpressing HNSCCs)(left panel). Tumor volume was measured after inoculation of control-GFP (n=3) or CD133-overexpressing HNSCCs (n=3),
respectively (right panel). Error bars correspond to SD (*, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0028053.g004
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e28053Figure 5. CD133/Src signaling regulates the mesenchymal transformation in HNSCCs and HN-CICs. (A) Morphological difference
between control-GFP and CD133-overexpressing HNSCCs. (B) Immunoblotting analysis (right panel) and confocal immunofluorescent staining (left
panel) of EMT-related markers in control-GFP or CD133-overexpressing HNSCCs were analyzed. (C) The protein levels of Vimentin and E-cadherin in
the indicated HN-CICs were analyzed by western blot. (D) Protein level of Src or p-Src in control-GFP or CD133-overexpressing HNSCCs were analyzed
by immunoblotting. (E) Single cell suspension of HN-CICs was infected with sh-Luc-expressing or shRNAi CD133 lentirus, respectively, and the
expression of Src or p-Src in above HN-CICs was analyzed by western blot. (F) CD133-overexpressing HNSCCs were first treated with 10 mM PP2 (Src
inhibitor) or 10 mM U0126 (Erk inhibitor) for 24 hours. The expression of Src, p-Src, Erk1/2, p-Erk1/2, vimentin, E-caherin, or CK-18 of above treated
cells was evaluated by western blot analysis with GAPDH being an internal loading control. (G) CD133-overexpressing HNSCCs were first cultured
with defined serum-free medium for 2 weeks along with the addition of PP2, and the expression of Oct-4, Nanog, or GAPDH proteins in control
(DMSO) or PP2 treated cells was analyzed by immunoblotting.
doi:10.1371/journal.pone.0028053.g005
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CICs (Figures 1 and 2). Whereas, overexpression of CD133
enhances tumor sphere-forming capability, side population cells,
stemness genes expression (Oct4 and Nanog) and promotes
tumorigenic ability of HNSCC (Figures 3 and 4). Collectively,
our data first demonstrated the crucial role of CD133 in the stem-
like enhancement and tumorigenesis of HNSCC and HN-CICs.
EMT, a de-differentiation program that converts adherent
epithelial cells into individual migratory cells, is critical for
embryonic development, the oncogenic progression of tumor
cells, and cancer metastasis [22]. Enhanced EMT characteristic is
associated with poor overall and metastasis-free survival in patients
with HNSCC [33]. Single or combined overexpression of stemness
factors, including Oct-4 and Nanog, were associated with cancer
stem-like properties and EMT [46,47]. Additionally, activation of
Src is frequently associated with human cancer because there is
evidence of a prominent role of Src in EMT and development of
metastasis. Further, CD133 has been described as a substrate of
Src. The identification of CD133 as a substrate for Src suggests
that the unknown function of the cytoplasmic domain of C133
might mediate important physiological function in subcellular
regulation [28]. In line with these reports, we firstly showed
CD133/Src axis regulated tumor initiating property and EMT
traits. The discovered roles of stemness signature coupled with
EMT process has gained huge interest in the field of cancer
research as it indicates that misplaced stemness properties
contribute to tumor metastasis and recurrence, making cancer
difficult to be tackled. A further understanding on the regulatory
networks between EMT and stemness signature may update our
current knowledge on the development of therapeutic treatments
for malignant cancers in the future.
Hypoxia is a well-recognized tumor microenvironment/niche
that is linked to tumor aggressiveness [48,49], and also favor
invasive growth and malignant progression by stimulating the Src
pathway. Recently, many reports demonstrated hypoxia is also
crucial in maintaining the stem cells and cancer stem cells niche
Figure 7. Schematic of the CD133/Src signaling pathways
promoting EMT, stemness properties, and tumorigenicity of
head and neck cancer initiating cells (HN-CICs). Up-regulation of
CD133, consequently, activates the Src signaling (p-Src), then, promotes
gain of EMT, enhancement of stemness properties and tumorigenicity
in HNSCC.
doi:10.1371/journal.pone.0028053.g007
Figure 6. CD133 downregulation and Src inhibition abrogate
the p-Src activity and sphere formation ability in primary HN-
CICs. (A) Protein level of CD133 and p-Src of lentivius mediated CD133
knockdown primary HN-CICs was analyzed by western blot. (B) Primary
HN-CICs were first infected with sh-Luc or CD133-shRNA lentivirus.
Three days after the lentiviral infection, the sphere formation ability of
virus infected cells then cultivated under selection medium were
recorded. (C) Newly enriched primary HN-CICs were treated with PP2
(10 mM) for 72 hrs and the sphere formation ability of PP2 treated HN-
CICs cells were examined. Arrows indicated the sphere cells.
doi:10.1371/journal.pone.0028053.g006
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tumorigenicity and CICs characteristics including Oct-4 up-
regulation [52]. Notably, HIF-1a promotes CD133-positive
human glioma-derived CICs propagation and self-renewal
[53,54]. Matsumoto et al elucidated a mechanistic relationship
between CD133 and the hypoxia-inducible factor-1a (HIF-1a)
[55]. Interestingly, HIF-2a shows strong tumor-promoting activity
and has been shown to bind to the Oct-4 promoter for Oct-4
induction in embryonic stem cells [56]. Other studies demonstrat-
ed that HIF-2a appears to be an attractive target because it is
specifically expressed by brain tumor stem cells but not neural
progenitor cells, whereas HIF-1a is up-regulated in these cellular
populations [57]. Additionally, Li et al observed HIF-2a co-
expressed with CD133 in human glioblastoma biopsy specimens
[57]. Our data also found CD133-overexpressing HNSCCs
enhanced the expression of HIF-1a or HIF-2a (Data not shown).
It is therefore possible that CD133 and HIF might also be the
coordinated regulation by hypoxia in HN-CICs. Further research
effort is needed in this area.
Extracellular membrane receptor, such as CD19, could interact
with and phosphorylated by Src family kinase then amplify the
activity of Src family kinases in B lymphocyte [35]. Boivin et al
report that there are five tyrosine residues (818, 819, 828, 846, and
852) within CD133 C-terminal domain, which could be potentially
phosphorylated by Src kinase. Empirically, the tyrosine-828
residue is the Src SH2 binding motif (YDDV motif)[28]. Here,
we tried to explore whether tyrosine phosphorylation in CD133
may promote Src kinase activity. However, we found that
CD133Y828F mutant protein did not invert Src activation (Figure
S4). It is reasonable that other tyrosine residues of CD133 may be
the major regulatory sites on Src activity. Therefore, more precise
and sophisticated experimental designs are required to dissect the
effect on CD133 up-regulation and tyrosine phosphorylation and
consequent activation of Src kinase.
Increased tumor initiating activity is a hallmark of CICs [4].
Knockdown of CD133 lessened tumor initiating activity both in
vitro and in vivo (Figures 1 and 2). However, deletion of CD133 did
not completely eliminate tumor promoting potential of HN-CICs
(Figure 2E). It is possible that CD133 signaling is among one of the
molecular mechanisms in regulation of HN-CICs in HNSCC,
although, others have observed that CD133 regulates Notch, Wnt,
ERK, and PTEN-PI3K-Akt signaling [15,58,59]. Other develop-
mental signaling pathways, including Hedgehog signaling and
Bmi1 signaling, have been reported to play critical roles in the
regulation of CICs characteristics, which were not significant
changed in CD133-knockdown or CD133-overexpression
HNSCCs (data not shown). It would be interesting to determine
the potential cross-linking of CD133 signaling with other signaling
pathways in the future. Overall, our present research showed
CD133/Src play a major role in the maintenance of HN-CICs
population through EMT modulation. Targeting CD133/Src
signaling might be a potential therapeutic target for HNSCC by
eliminating CICs.
Supporting Information
Figure S1 Establishment of CD133 overexpressing
HNSCCs or CD133 stable knockdown HN-CICs. HNSCC
cells, (A) SAS and (B) OECM1, were infected with lentivirus co-
expressing GFP and CD133. Afterward virus transduction, GFP
positive HNSCCs were sorted according to the expression of GFP
to isolate stable HNSCCs. GFP positive HNSCC cells demon-
strated the successful lentivirus infection. (C) Single cell of HN-
CICs (derived from SAS cells) were infected with lentivirus co-
expressing GFP and small hairpin RNA targeting CD133. The
successful infected cells were sorted by flow cytometry according to
the co-expression of GFP protein.
(TIF)
Figure S2 Expression of Oct4 and CK18 in tumors
derived from CD133 ovexpressing HNSCCs or CD133
stable knockdown HN-CICs. Tumors derived from control
HN-CICs (sh-Luc) or CD133-knockdown SAS-HN-CICs, and
SAS cells were collected, sectioned and stained with Hematoxylin
and anti-Oct4 (A) or anti-CK18 (B) as described. Arrows indicate
the positive staining. (C) Tissue sections of control-GFP and
CD133-overexpressing SAS cells xenograft tumor were stained
with CK18 or Oct4.
(TIF)
Figure S3 Src kinase activation promotes EMT, tumor-
igenicity and stemness. (A) Expression of p-Src, E-cadherin
and Vimentin in HNSCCs transfected with either Src-overex-
pressing or control vector was examined by western blot. The
amount of GAPDH protein was referred as loading control. (B)
Anchorage-independent growth of control-vecor or Src-overex-
pressing HNSCCs was analyzed (**, p,0.01). (C) Sphere
formation ability of control or Src-overexpressing HNSCCs was
examined under the serum-free defined selection medium (**,
p,0.01). (D) Representative tumor growth of control- or Src-
overexpressing (Src
over) HNSCCs in the subcutaneous space of
recipient mice (Red arrows: control HNSCCs; Yellow arrows: Src-
overexpressing HNSCCs). (E) SAS HN-CICs (5*10
5 cells) were
subcutaneously injected into both backs of nude mice and allowed
to develop tumors to a size around 0.2 cm
3 (12 days). On day 12,
15, and 18 after the inoculation of HN-CIC cells, PP2 (10 mM)
was injected into the right back tumors whereas DMSO was
injected into the left back as negaive control (Red arrows: DMSO
treatment as control; Yellow arrows: PP2 treated HN-CICs).
(TIF)
Figure S4 Effect of CD133Y828F mutant on p-Src
activity. (A) DNA sequencing confirmed the CD133Y828F
mutation, which encodes CD133Y828F mutant protein. (B) 293A
cells transfected with plasmids, control-GFP, CD133 wild type
(CD133over) or CD133Y828F (CD133Y828F), respectively, were
collected (under no serum culture condition). The protein levels of
p-Src, total Src and CD133 were examined by immunoblot.
(TIF)
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